Comparing Becton, Dickinson and (NYSE:BDX) & AngioDynamics (ANGO)

AngioDynamics (NASDAQ: ANGO) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitabiliy, earnings, dividends, valuation and analyst recommendations.

Dividends

Becton, Dickinson and pays an annual dividend of $2.92 per share and has a dividend yield of 1.5%. AngioDynamics does not pay a dividend. Becton, Dickinson and pays out 83.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AngioDynamics has increased its dividend for 45 consecutive years.

Institutional & Insider Ownership

85.8% of AngioDynamics shares are owned by institutional investors. Comparatively, 75.7% of Becton, Dickinson and shares are owned by institutional investors. 1.9% of AngioDynamics shares are owned by company insiders. Comparatively, 1.4% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares AngioDynamics and Becton, Dickinson and’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$349.64 million	1.74	$52.89 million	$0.19	87.16
Becton, Dickinson and	$12.32 billion	3.43	$3.20 billion	$3.50	56.53

Becton, Dickinson and has higher revenue and earnings than AngioDynamics. Becton, Dickinson and is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for AngioDynamics and Becton, Dickinson and, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	0	2	3	0	2.60
Becton, Dickinson and	1	3	6	1	2.64

AngioDynamics presently has a consensus price target of $18.40, indicating a potential upside of 11.11%. Becton, Dickinson and has a consensus price target of $191.91, indicating a potential downside of 3.00%. Given AngioDynamics’ higher probable upside, research analysts plainly believe AngioDynamics is more favorable than Becton, Dickinson and.

Profitability

This table compares AngioDynamics and Becton, Dickinson and’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioDynamics	2.00%	5.19%	3.79%
Becton, Dickinson and	6.25%	22.53%	7.25%

Risk and Volatility

AngioDynamics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Summary

Becton, Dickinson and beats AngioDynamics on 11 of the 18 factors compared between the two stocks.

About AngioDynamics

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.